[go: up one dir, main page]

BR9809389A - Tratamento de distúrbios do sistema nervoso central com modulados de receptores de estrogênio seletivos - Google Patents

Tratamento de distúrbios do sistema nervoso central com modulados de receptores de estrogênio seletivos

Info

Publication number
BR9809389A
BR9809389A BR9809389-4A BR9809389A BR9809389A BR 9809389 A BR9809389 A BR 9809389A BR 9809389 A BR9809389 A BR 9809389A BR 9809389 A BR9809389 A BR 9809389A
Authority
BR
Brazil
Prior art keywords
treatment
selective estrogen
nervous system
central nervous
estrogen receptor
Prior art date
Application number
BR9809389-4A
Other languages
English (en)
Inventor
Kelly Renee Bales
Henry Uhlman Bryant
Eteven Marc Paul
Mary Patricia Knadler
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9809389A publication Critical patent/BR9809389A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: "TRATAMENTO DE DISTúRBIOS DO SISTEMA NERVOSO CENTRAL COM MODULADORES DE RECEPTORES DE ESTROGêNIO SELETIVOS". A presente invenção refere-se a um método de tratamento de depressão, variações de humor ou mal de Alzheimer em um paciente com necessidade de tal tratamento, por administração de um composto de fórmula (a) modulador de receptores de estrogênio seletivos, onde R^ 1^ e R^ 2^ são independentemente hidróxi e alcóxi de um a quatro átomos de carbono; e R^ 3^ e R^ 4^ são independentemente metila ou etila, ou R^ 3^ e R^ 4^, tomados junto com o átomo de nitrogênio ao qual estão ligados, formam um anel pirrolidino, metilpirrolidino, dimetilpirrolidino, piperidino, morfolino ou hexametilenoimino.
BR9809389-4A 1997-04-09 1998-04-07 Tratamento de distúrbios do sistema nervoso central com modulados de receptores de estrogênio seletivos BR9809389A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4311797P 1997-04-09 1997-04-09
PCT/US1998/007024 WO1998045287A1 (en) 1997-04-09 1998-04-07 Treatment of central nervous system disorders with selective estrogen receptor modulators

Publications (1)

Publication Number Publication Date
BR9809389A true BR9809389A (pt) 2002-03-19

Family

ID=21925589

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9809389-4A BR9809389A (pt) 1997-04-09 1998-04-07 Tratamento de distúrbios do sistema nervoso central com modulados de receptores de estrogênio seletivos

Country Status (19)

Country Link
US (2) US6077852A (pt)
EP (1) EP0986556A4 (pt)
JP (1) JP2001518898A (pt)
KR (1) KR20010006219A (pt)
CN (1) CN1260792A (pt)
AU (1) AU733421B2 (pt)
BR (1) BR9809389A (pt)
CA (1) CA2286455A1 (pt)
EA (1) EA002360B1 (pt)
HU (1) HUP0002031A3 (pt)
ID (1) ID27986A (pt)
IL (1) IL132278A0 (pt)
NO (1) NO994901L (pt)
NZ (2) NZ500175A (pt)
PL (1) PL336701A1 (pt)
TR (1) TR199902700T2 (pt)
TW (1) TW479056B (pt)
WO (1) WO1998045287A1 (pt)
ZA (1) ZA982877B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096781A (en) * 1997-11-14 2000-08-01 Eli Lilly And Company 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome
US6288108B1 (en) 1998-06-16 2001-09-11 Eli Lilly And Company Methods for increasing levels of acetylcholine
KR20010052891A (ko) 1998-06-16 2001-06-25 피터 지. 스트링거 아세틸콜린 수치를 상승시키는 방법
TR200003714T2 (tr) * 1998-06-16 2001-07-23 Eli Lilly And Company Asetilkolin seviyesinin yükseltilmesi
US6087378A (en) * 1998-10-13 2000-07-11 Eli Lilly And Company Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome
US6610706B1 (en) 1999-07-29 2003-08-26 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
WO2001009115A2 (en) * 1999-07-29 2001-02-08 Eli Lilly And Company A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1- YL)ETHOXY] PHENOXY)-2- (4-METHOXYPHENYL) BENZO[b]THIOPHENE HYDROCHLORIDE
US6653479B1 (en) 1999-07-29 2003-11-25 Eli Lilly And Company Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride
AU6335600A (en) * 1999-07-29 2001-02-19 Eli Lilly And Company A novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-metho yphenyl)benzo[b]thiophene hydrochloride
EP1757291A3 (en) * 2000-05-08 2009-07-15 Eli Lilly & Company Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof
JP2003535827A (ja) * 2000-05-08 2003-12-02 イーライ・リリー・アンド・カンパニー ６−ヒドロキシ−３−（４−［２−（ピペリジン−１−イル）エトキシ］フェノキシ）−２−（４−メトキシフェニル）ベンゾ［ｂ］チオフェンおよびその塩の安定化製剤
EA005116B1 (ru) * 2000-10-20 2004-10-28 Эли Лилли Энд Компани НОВАЯ КРИСТАЛЛИЧЕСКАЯ ФОРМА ГИДРОХЛОРИДА 6-ГИДРОКСИ-3-(4-[2-(ПИПЕРИДИН-1-ИЛ)ЭТОКСИ]ФЕНОКСИ)-2-(4-МЕТОКСИФЕНИЛ)БЕНЗО[b]ТИОФЕНА
BRPI0808740A2 (pt) * 2007-03-16 2014-08-12 Lilly Co Eli Processo e intermediários para preparação de arzoxifeno.
EA022760B1 (ru) 2007-10-16 2016-02-29 Репрос Терапьютикс Инк. Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
DE102010027016A1 (de) 2010-07-09 2012-01-12 Universitätsklinikum Jena Steroid-Styrylfarbstoff-Konjugate zur Simulation und direkten lichtoptischen Detektion des Verhaltens von Steroiden im lebenden biologischen Gewebe und in Gegenwart von steroidbindenden Proteinen
AU2013225869B2 (en) 2012-02-29 2017-06-08 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
MA38325B1 (fr) 2013-02-19 2019-03-29 Novartis Ag Dérivés de benzothiophène et compositions correspondantes en tant qu'agents de dégradation sélectifs des récepteurs des œstrogènes
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) * 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
CN104829569B (zh) * 2015-05-12 2017-04-26 广州中医药大学 一种2‑苯基‑苯骈五元杂环类化合物及其衍生物的应用
CN104829568B (zh) * 2015-05-12 2017-03-01 广州中医药大学 一种2‑苯基‑苯骈五元杂环类化合物及其衍生物的医药应用
JP7048505B2 (ja) 2015-11-10 2022-04-05 パラクリン セラピューティクス エービー Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置
ES2975558T3 (es) 2016-09-15 2024-07-09 Arvinas Inc Derivados de indol como degradantes de receptor de estrógeno
IL266842B (en) 2016-12-01 2022-09-01 Arvinas Operations Inc Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
KR20230140606A (ko) 2017-01-26 2023-10-06 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 단백질 분해 조절제 및 관련 사용 방법
JP2021534177A (ja) * 2018-08-16 2021-12-09 ジー１ セラピューティクス， インコーポレイテッド 医学的障害を治療するためのベンゾチオフェンエストロゲン受容体モジュレーター
CN118986983A (zh) 2019-08-26 2024-11-22 阿尔维纳斯运营股份有限公司 用四氢萘衍生物作为雌激素受体降解剂的治疗乳腺癌的方法
BR112023004656A2 (pt) 2020-09-14 2023-05-09 Arvinas Operations Inc Formas cristalinas e amorfas de um composto para a degradação direcionada do receptor de estrogênio

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862232A (en) * 1963-07-03 1975-01-21 Upjohn Co 1-(p-hydroxyphenyl)-2-phenyl-6-(2-diethylaminoethoxy)-3,4-dihydronaphthalene and the salts thereof
US3293263A (en) * 1963-12-09 1966-12-20 Upjohn Co Diphenylbenzocycloalkenes
US3320271A (en) * 1964-06-01 1967-05-16 Upjohn Co 1, 2-diphenyl-3, 4-dihydronaphthalenes and 2, 3-diphenylindenes
GB1138163A (en) * 1965-05-21 1968-12-27 Bristol Myers Co Benzothiophene derivatives having anti-fertility properties
US3394125A (en) * 1965-10-23 1968-07-23 Bristol Myers Co 2-phenyl-3-tertiary-aminoalkoxy phenyl-and corresponding tertiaryaminoalkyl thio benzfurans substituted in the benzo nucleus with an alkoxy or tertiaryamino alkoxy or alkylthio group
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4230862A (en) * 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4117128A (en) * 1976-08-03 1978-09-26 Smithkline Corporation Sulfonyl benzofurans and benzothiophenes having coronary vasodilator activity
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB8311678D0 (en) * 1983-04-28 1983-06-02 Ici Plc Phenol derivatives
GB8705174D0 (en) * 1987-03-05 1987-04-08 Ici Plc Heterocyclic compounds
US5013761A (en) * 1988-06-03 1991-05-07 Eli Lilly And Company Serotonin antagonists
FR2665444B1 (fr) * 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
US5254568A (en) * 1990-08-09 1993-10-19 Council Of Scientific & Industrial Research Benzopyrans as antiestrogenic agents
DE4117512A1 (de) * 1991-05-25 1992-11-26 Schering Ag 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US6489355B2 (en) * 1993-12-01 2002-12-03 Eli Lilly And Company Methods of inhibiting the effects of amyloidogenic proteins
US5578613A (en) * 1993-12-21 1996-11-26 Eli Lilly And Company Methods for inhibiting weight gain or inducing weight loss
US5534526A (en) * 1993-12-21 1996-07-09 Eli Lilly And Company Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome
US5441965A (en) * 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
US5462950A (en) * 1993-12-21 1995-10-31 Eli Lilly And Company Methods of treating menstrual symptoms and compositions therefore
US5439931A (en) * 1993-12-21 1995-08-08 Eli Lilly And Company Method for increasing libido in post-menopausal women
US5552415A (en) * 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
US5389670A (en) * 1993-12-21 1995-02-14 Eli Lilly Company Methods of inhibiting the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder
US6417198B1 (en) * 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5384332A (en) * 1994-05-11 1995-01-24 Eli Lilly And Company Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives
US5512296A (en) * 1994-08-22 1996-04-30 Eli Lilly And Company Methods for inhibiting neuronal damage
US5434166A (en) * 1994-08-22 1995-07-18 Eli Lilly And Company Methods of inhibiting demyelinating and desmyelinating diseases
US6562862B1 (en) * 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
JP3989569B2 (ja) * 1995-02-28 2007-10-10 イーライ リリー アンド カンパニー ベンゾチオフェン化合物、中間体、組成物および方法
US5731342A (en) * 1996-02-22 1998-03-24 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods

Also Published As

Publication number Publication date
US6077852A (en) 2000-06-20
AU7104998A (en) 1998-10-30
ZA982877B (en) 1999-10-04
WO1998045287A1 (en) 1998-10-15
KR20010006219A (ko) 2001-01-26
NO994901L (no) 1999-12-09
CA2286455A1 (en) 1998-10-15
JP2001518898A (ja) 2001-10-16
HUP0002031A3 (en) 2003-01-28
EA199900913A1 (ru) 2000-04-24
TR199902700T2 (xx) 2000-06-21
NZ500175A (en) 2001-10-26
US20020013342A1 (en) 2002-01-31
NZ514146A (en) 2001-09-28
CN1260792A (zh) 2000-07-19
TW479056B (en) 2002-03-11
EP0986556A1 (en) 2000-03-22
HUP0002031A2 (hu) 2001-06-28
PL336701A1 (en) 2000-07-03
EP0986556A4 (en) 2001-03-21
NO994901D0 (no) 1999-10-08
AU733421B2 (en) 2001-05-17
EA002360B1 (ru) 2002-04-25
ID27986A (id) 2001-05-03
IL132278A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
BR9809389A (pt) Tratamento de distúrbios do sistema nervoso central com modulados de receptores de estrogênio seletivos
MY132529A (en) Paroxetine hydrochloride anhydrate
BRPI0413523A (pt) derivados de oxima de (4-hidroxifenil)-1h-indol-3-carbaldeìdo como agentes estrogênicos
DE69825292D1 (de) Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
PT1333887E (pt) Metodo de tratamento de desordens musculares
MX9603479A (es) Derivados de 4-amino de acido micofenolico con actividad inmunosupresora.
ATE219068T1 (de) Naphtylamides als zentralnervensystemmittel
NO883306D0 (no) Farmasoeytisk aktive konjugater med forbedret bindingsspesifisitet for kroppsvev.
ATE239474T1 (de) Verwendung von levobupivacain
YU48698A (sh) Karboksamidni derivati pirolidina, piperidina i heksahidroazepina za lečenje oboljenja na bazi tromboze
DK217588D0 (da) 17beta-(cyclopropylamino)-androst-5-en-3beta-olderivater, deres fremstilling og anvendelse som laegemidler
DE69612510D1 (de) Verwendung von 1-(2-naphtylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridin zur herstellung eines medikaments zur behandlung der amyotrophen lateralsklerode
DE59608150D1 (de) Transdermales therapeutisches system (tts) zur verabreichung von testosteron
BR9808515A (pt) Tratamento ou profilaxia de câncer de próstata e hiperplasia benigna da próstata com moduladores de receptores de estrogênio seletivos
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
DE69920033D1 (de) Verfahren zur verminderung von krebssymptomen
NO975371L (no) Farmasöytisk sammensetning fremstilt ved tilföring av en smakstilsetningsbærer til et medikament
EA199900910A1 (ru) Профилактика рака молочной железы селективными модуляторами рецепторов эстрогена
PT1140830E (pt) Derivados de arilpiperidina e aril-1,2,5,6-tetra-hidro-piridina amida possuindo actividade receptora de 5ht1a
BR9813638A (pt) "processo para a preparação de cloridrato de paroxetina"
PT1244498E (pt) Combinacao de trimebutina com um analgesico opiode
AU2796695A (en) Pyrrolidine derivatives for the treatment of cholecystokinine and gastrine-related disorders
UA29106A (uk) Спосіб лікування вібраційної хвороби

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A,8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1890 DE 27/03/2007.